Chad Messer

- Lantern Pharma (LTRN) leverages AI for drug discovery, having developed **12 drug programs** since late 2018/early 2019, with **three currently in clinical trials**.  **[0001763950_2216794_0]** 
- The company is advancing several drug candidates, including **LP-300** in a **Phase 2 trial** for non-small cell lung cancer in non-smokers, **LP-184** which completed a 63-patient Phase 1 trial with **48% clinical benefit** in advanced solid tumors, and **LP-284** which achieved a **complete metabolic response** in non-Hodgkin’s lymphoma.  **[0001763950_2216794_0]** **[0001763950_2216794_1]** **[0001763950_2216794_5]** **[0001763950_2216794_6]** 
- Lantern Pharma is launching its AI platform as an **open-access freemium model** for cancer drug developers and is spinning out **Starlight Therapeutics**, a new company focused on brain cancers, which will be owned by existing Lantern shareholders.  **[0001763950_2216794_0]** **[0001763950_2216794_1]** 
- As of last quarter, the company reported approximately **$15.9 million** in cash with a quarterly burn rate of **$4 to $4.5 million**.  **[0001763950_2216794_6]**

Lantern Pharma Updates on AI Drug Discovery Pipeline and Strategic Initiatives

- Lantern Pharma will present two commercially deployed AI research platforms, **predictBBB.ai** and **LBx-AI**, at the inaugural AI for Biology and Medicine symposium.  **[1763950_d1a05c0c1ffd4039aacd4eaed48814c6_0]** 
- **predictBBB.ai** achieves **94.1% accuracy** in predicting blood-brain barrier permeability and can screen **200,000 drug candidates in under a week**.  **[1763950_d1a05c0c1ffd4039aacd4eaed48814c6_1]** 
- **LBx-AI** demonstrates **86% accuracy** in predicting treatment response for non-small cell lung cancer patients and can infer solid tumor characteristics.  **[1763950_d1a05c0c1ffd4039aacd4eaed48814c6_1]** 
- These platforms, which aim to accelerate drug discovery and reduce costs, will be made available as **open-access services** for partners and collaborators.  **[1763950_d1a05c0c1ffd4039aacd4eaed48814c6_0]** **[1763950_d1a05c0c1ffd4039aacd4eaed48814c6_1]**

Lantern Pharma to Present AI-Driven Cancer Drug Development Platforms

- **Lantern Pharma Inc.** presented promising Phase 1 clinical trial data for **LP-284**, an AI-developed oncology drug candidate, at the 25th Annual Lymphoma, Leukemia & Myeloma Congress.  **[1763950_35a4d7ceb9304dad9dca29b184d1e964]** 
- LP-284 demonstrated a **complete metabolic response** in a patient with aggressive Grade 3 diffuse large B-cell lymphoma (DLBCL) who had previously failed multiple advanced treatments.  **[1763950_35a4d7ceb9304dad9dca29b184d1e964]** 
- The drug targets DNA repair deficiencies, making it effective regardless of TP53 mutation status and resistant to BTK and proteasome inhibitors, addressing a significant treatment gap in the **$3-4 billion market** of relapsed or refractory B-cell cancers.  **[1763950_35a4d7ceb9304dad9dca29b184d1e964]** 
- Lantern Pharma maintains **strong financial health** with a low debt-to-equity ratio and substantial cash reserves, and the clinical response has generated significant interest from biopharmaceutical companies and clinical investigators.  **[1763950_35a4d7ceb9304dad9dca29b184d1e964]**

Lantern Pharma Reports Positive Phase 1 Data for Oncology Drug LP-284

- Lantern Pharma presented clinical data for its drug candidate **LP-284** at the 25th LL&M Congress, highlighting a **complete metabolic response** in a patient with aggressive diffuse large B-cell lymphoma (DLBCL) who had failed prior CAR-T and bispecific antibody therapies.  **[1763950_c2ad3314f8fd462da36e9f14c7b88d12_0]** 
- This clinical outcome validates LP-284's mechanism of action and addresses a critical treatment gap in the post-immunotherapy setting, targeting a **$3-4 billion annual market** in relapsed/refractory B-cell cancers.  **[1763950_c2ad3314f8fd462da36e9f14c7b88d12_0]** **[1763950_c2ad3314f8fd462da36e9f14c7b88d12_1]** 
- LP-284, currently in **Phase 1 evaluation**, demonstrates dual strategic potential as a monotherapy and in combination with existing FDA-approved agents, with a favorable early safety profile and ongoing partnership discussions.  **[1763950_c2ad3314f8fd462da36e9f14c7b88d12_1]** **[1763950_c2ad3314f8fd462da36e9f14c7b88d12_2]** **[1763950_c2ad3314f8fd462da36e9f14c7b88d12_3]**

Lantern Pharma Presents Positive LP-284 Clinical Data

- Lantern Pharma (LTRN) is advancing **three clinical-stage cancer drug candidates**: **LP-300** (Phase II, targeting a **$4-5 billion market** in non-small cell lung cancer), **LP-184** (completed Phase I, with planned Phase Ib/II trials), and **LP-284** (in trials for blood cancers, a **$3-4 billion market**).  **[1763950_tx_377949_1]** **[1763950_tx_377949_2]** **[1763950_tx_377949_3]** 
- The company maintains a disciplined fiscal profile with a burn rate of approximately **$4.5 million per quarter** and has cash projected to last into **2026**.  **[1763950_tx_377949_1]** **[1763950_tx_377949_6]** 
- Lantern Pharma has secured **11 FDA designations** (**5 orphan, 4 rare pediatric, 2 Fast Track**) and leverages its AI platform, RADAR, for drug development, holding approximately **140 issued and pending patent applications**.  **[1763950_tx_377949_1]** **[1763950_tx_377949_6]** **[1763950_tx_377949_7]** 
- The company plans to make aspects of its AI platform publicly available to drive collaborations and generate revenue through token sales.  **[1763950_tx_377949_2]** **[1763950_tx_377949_6]**